Biotech Values

[mcbio]

The trial was very small (n = 38), but on the positive side both TTP and OS were significantly different. If the phase III trial is successful, it will address a sizeable unmet need, i.e. the ~40% of refractory CRC patients who carry KRAS mutations. It would also provide a fourth line option for KRAS wild-type patients, but I think that is likely to be a smaller market.

Where do you get that perifosine works specifically in KRAS CRC patients? I thought all their data to date is just in a general mCRC patient population and not specifically targeted to KRAS CRC patients.